Physician profile
Taylor Hodges
NPI 1114652104
$32,656.58
in general payments reported to CMS, 2019-2025
27 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $203 · 2023: $1,680 · 2024: $2,401 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $7,175 · Travel and Lodging: $6,115 · Education: $99.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,063.44 |
| Food and Beverage | $7,175.07 |
| Travel and Lodging | $6,115.46 |
| Education | $99.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $26,812.00 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $873.13 | 2022-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $575.96 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $569.58 | 2022-2025 | Brilinta, Farxiga |
| Pfizer INC. | $563.40 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.82 | 2023-2025 | Jardiance |
| Heartflow, INC. | $472.64 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $386.39 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $296.48 | 2023-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $273.49 | 2025 | |
| Medtronic, INC. | $267.76 | 2022-2025 | Aurora Ev-Icd Mri Surescan, Reveal Linq, Linq II |
| Scpharmaceuticals INC. | $167.08 | 2024-2025 | |
| Esperion Therapeutics, INC. | $145.25 | 2022-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $141.25 | 2023-2024 | Xarelto |
| Lilly USA, LLC | $121.17 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $88.84 | 2023-2024 | Inpefa |
| Abiomed | $76.20 | 2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $48.07 | 2025 | Uptravi, Opsynvi, Opsumit |
| Boston Scientific Corporation | $43.71 | 2023-2024 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $36.68 | 2025 | |
| Glaxosmithkline, LLC. | $35.19 | 2025 | Arexvy, Shingrix |
| Tactile Systems Technology INC | $34.76 | 2025 | Flexitouch Plus, Nimbl |
| Bridgebio Pharma, INC. | $29.26 | 2025 | Attruby |
| Medicomp INC | $27.77 | 2024 | Telepatch Cardiac Monitor |
| Terumo Medical Corporation | $20.68 | 2024 | Glidesheath Slender, Heartrail, Glidewire |
| Merck Sharp & Dohme LLC | $17.89 | 2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $13.13 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.